MedTrace Logo

Topical ENS-002 for Atopic Dermatitis in Adults

NCT06469385 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2025-08-14

No results posted yet for this study

Summary

The goal of this study is to determine the safety and effects of ENS-002, a live biotherapeutic product (LBP) consisting of commensal, clonal, non-pathogenic bacteria in participants with atopic dermatitis.

Conditions

Interventions

BIOLOGICAL

ENS-002

Live biotherapeutic product (LBP) consisting of commensal, clonal, non-pathogenic bacteria. Low Dose ENS-002 High Dose ENS-002

Sponsors & Collaborators

  • Concerto Biosciences

    lead INDUSTRY

Principal Investigators

  • Bernardo Cervantes, PhD · Concerto Biosciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-18
Primary Completion
2025-08-04
Completion
2025-08-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06469385 on ClinicalTrials.gov